FDA Calls Retroactive Exclusivity Unfair To Generics Makers
The U.S. Food and Drug Administration on Tuesday defended its refusal to retroactively apply a new policy on exclusivity for brand-name drugs with multiple active ingredients, arguing in D.C. federal court...To view the full article, register now.
Already a subscriber? Click here to view full article